Valporoic acid: Review

Revista Neurociencias

Volumn 16, Issue 2, 2008, Pages 130-136

  Fagundes, Sayonara Beatriz Ranciaro ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Anticonvulsants; Enzyme inhibitors; GABA agents

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DEPAKOTE SPRINKLE; EPILENIL; LAMOTRIGINE; METHOTREXATE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPAKINE; VALPRENE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIDOVUDINE;

ABDOMINAL CRAMP; ALZHEIMER DISEASE; ANTICONVULSANT ACTIVITY; BLEEDING; BRAIN DISEASE; CHOREA MINOR; DIARRHEA; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DYSKINESIA; GENERALIZED EPILEPSY; HUMAN; HYPERAMMONEMIA; INFECTION; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MIGRAINE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OLFACTORY HALLUCINATION; PANCREATITIS; PANIC; PERIPHERAL NERVE INJURY; PSEUDOLYMPHOMA; REVIEW; SEIZURE; SIDE EFFECT; TERATOGENICITY; TOXOPLASMOSIS; VOMITING; WEIGHT GAIN; WEST SYNDROME;

EID: 77953442983     PISSN: 01043579     EISSN: None     Source Type: Journal    
DOI: 10.34024/rnc.2008.v16.8650     Document Type: Review

References (66)

1. Burton BS. On the propyl derivates and decomposition products of ethylacetate. Am Chem J 1882;3:385-95.
2. Meunier H, Carraz G, Meunier V, Eymard M. Propriétés pharmacodynamiques de l'ácide n-propylacétique. Thérapie 1963:18:435-8.
3. Carraz G, Fau R, Chateau R, Bonnin J. Communication concerning 1st clinical test of the anticonvulsive activity of n-dipropylacetic acid (sodium salt). Ann Med Psychol (Paris) 1964;122:577-85.
4. Cukiert A. Epilepsias Generalizadas. São Paulo: Segmento Farma, 2006, 220p.
5. Dean JC. Valproate. In: Wylllie E (ed.). Treatment of epilepsy. Principles and Practice. Philadelphia: Lea&Febiger, 1993, 915-22.
6. Tung TC, Moreno RA.O papel do divalproato de sódio no tratamento dos transtornos do humor: eficácia, tolerabilidade e segurança. Rev Psiq Clin 2002;29(1):42-53.
7. Loscher W. Basic pharmacology of valproate: a review after 35 year of clinical use for the treatment of epilepsy. CNS Drugs 2002;16(10):669-94.
8. Perucca E. Pharmacological and therapeutic properties of Valproate: a summary after 35 years of clinical experience. CNS Drugs2002;16(10):695-714.
9. Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: Role of 5-HT (1 A) receptor agonism. Brain Res 2005;1049(2):182-90.
10. Patsalos PN, Peruca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2(6):347-56.
11. Kishore P, Rajani Kumar V, Satyanarayana V, Krishna DR. HPLC determination of Valproic Acid in human serum. Pharmazie 2003;58(6):378-80.
12. Schobben F, van der Klejn E, Gabreels FJ. Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol1975;8(2):97-105.
13. King M. The new patient with a first seizure. Aust Fam Physician 2003;32(4):221-8.
14. Mory SB, Guerreiro CA, Li LM, Teixeira RA, Costa AL, Cardoso TA, et al. Idiopathic generalized epilepsies misdiagnosed as partial epilepsies. Arq Neuropsiquiatr 2002;60(3-B):788-96.
15. Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 2003;44(suppl 2):27-32.
16. Lance JW, Anthony M. Sodium Valproate in the management of intractable epilepsy: comparison with clonazepam. Proc Aust Assoc Neurol 1975;12:55-60.
17. Alva Moncayo E, Ruuiz-Ruiz A. The value of Topiramate used with conventional schemes as an adjunctive therapy in the treatment of "Lennox Gastaut syndrome". Rev Neurol 2003;36(5):453-7.
18. Singh MB, Kalita J, Misra UK. Landau Kleffner syndrome: electroclinical and etiopathogenic heterogeneity. Neurol India 2002;50(4):417-23.
19. Seki T. Treatment of West Syndrome: present and future perspectives. No To Hattatsu 1997;29(2):91-9.
20. Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium Valproate in the management of painful neuropathy in type 2 diabetes a randomized placebo controlled study. Acta Neurol Scand 2002;106(5):248-52.
21. Cui SS, Yang CP, Bowen RC, Bai O, Li XM, Jiang W, Zhang X. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats. Brain Res 2003;975(1-2):229-36.
22. Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of Valproate: a novel role for an old drug. Med Res Rev 2002;22(5):492-511.
23. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003;22(13):3411-20.
24. Yildirim E, Zhang Z, Uz T, Chen CQ, Manev R, Manev H. Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. Neurosci Lett 2003;345(2):141-3.
25. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003;66(2):179-89.
26. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2(7):404-9.
27. Cheng L, Lumb M, Polgar L, Mudge AW. How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 2005;29(2):155-61.
28. Loy R, Tariot PN. Neuroprotective properties of valproate: potential benefit for AD and tauopathies. J Mol Neurosci 2002;19(3):303-7.
29. Green MW. The emergency management of headaches. Neurologist 2003;9(2):93-8.
30. Diener HCH. Pharmacological approaches to migraine. J Neural Transm Suppl 2003;(64):35-63.
31. Gallinat J, Stotz-IngenlathG, Lang UE, Hegerl U. Panic attacks, spike-wave activity, and limbic dysfunction. A case report. Pharmacopsychiatr 2003;36(3):123-6.
32. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 2003;62(3):237-44.
33. Peixoto ME Abilio VC, Silva RH, Frussa-Filho R. Effects of Valproic acid on an animal model of tardive dyskinesia. Behav Brain Res 2003;142(1-2):229-33.
34. Majumdar S, Jones NS, McKerrow WS, Scadding G. The management of idiopathic olfactory hallucinations: a study of two patients. Laryngoscope 2003;113(5):879-81.
35. Esiobu N, Hoosein N. An assessment of the in vitro antimicrobial effects of two antiepileptic drugs - Sodium Valproate and phenytoin. Antonie Van Leeuwenhoek 2003;83(1):63-8.
36. Munts AG, Wennekes MJ, Koehler PJ. A child with peculiar movements: Sydenhan chorea. Ned Tijdschr Geneeskd 2003;147(6):257-60.
37. Mileusnic D, Donoghue ER, Lifschultz BD. Pathological case of the moth: sudden death in child as a result of pancreatitis during valproic acid therapy. Pediatr Pathol Mol Med 2002;21(5):477-84.
38. Jezequel AM, Bonazzi P, Novelli G, Venturini C, Orlandi F. Early structural and functional changes in liver of rats treated with a single dose of valproic acid. Hepatol 1984;4(6):1159-66.
39. Hirsch E, Genton F. Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential? CNS Drugs 2003;17(9):633-40.
40. Trinka E, Dilitz E, Unterberger I, Luef G, Deisenhammer F, Niedermuller U, et al. Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002;249(10):1417-22.
41. Graziani G, Tentori L, Portarena I, Vergati M, Navarra P. Valproic Acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinol 2003; 144(7):2822-8.
42. Van Gerpen JA. Drug-Induced parkinsonism. Neurologist 2002;8(6):363-70.
43. Pohlmann Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleending. Acta Neurol Scand 2003;108(2):142-5.
44. Vesta KS, Medina PJ. Valproic Acid-induced neutropenia. Ann Pharmacother 2003;37(6):819-21.
45. Holmes LB. Teratogen-induced limb defects. Am J Med Genet 2002;112(3):297-303.
46. Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 2005;19(9):1166-8.
47. Whitsel Al, Johnson CB, Forehand QJ. An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid. Teratology 2002;66(4):153-63.
48. Padmanabhan R, Shafiullah MM. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 2003;43(1):29-40.
49. Weber M, Dib M. Folic acid and prevention of anomalies of foetal neural tube closing in women treated for epilepsy. Rev Neurol (Paris) 2003;159(2):165-70.
50. Malm H, Kajantie E, Kivirikko S, Kaariainen H, Peippo M, Somer M. Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology 2002;59(4):630-3.
51. Burneo JG, Limdi N, Kuzniecky RI, Knowlton RC, Mendez M, Lawn N, et al. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. Neurology 2003;60(12):1991-2.
52. Yoshikawa H, Watanabe T, Abe T. Fanconi Syndrome caused by Sodium Valproate: report of three severely disabled children. Eur J Paediatr Neurol 2002;6(3):165-7.
53. Walstra GJ. Reversible dementia due to valproic acid therapy. Ned Tijdschr Geneeskd 1997;141(8):391-3.
54. Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol 2003;148(4):730-6.
55. Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus Valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 2003;18(2):133-9.
56. Kulkami SK, Kant G. Pharmacodynamics of drug-induced weight gain. Drugs Today (Barc) 2001;37(8):559-71.
57. Akdeniz F, Taneli F, Noyan A, Yuncu Z, Vahip S. Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women? Prog Neuropsychopharmacol Biol Psychiatr 2003;27(1):115-21.
58. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs 2003;63(12):1185-227.
59. Verroti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 2002;17(4):367-73.
60. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64(7):1134-8.
61. Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005;4(3):571-81.
62. Baba M, Karakas M, Aksungur VL, Homan S, Yucel A, Acar MA, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol 2003;17(4):399-401.
63. Shinka T, Ohfu M, Hirose S, Kuhara T. Effect of Valproic Acid on the urinary metabolic profile of a patient with succinic semialdehyde dehydrogenase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci 2003;792(1):99-106.
64. Romanelli F, Pomeroy C.Concurrent use of Antiretrovirals and Anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Curr Pharm 2003;9(18):1433-9.
65. Njolstad PR, Skjeldal OH, Agsteribbe E, Huckriede A, Wannag E, Sovik O, et al. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity. Pediatr Neurol 1997;16(2):160-2.
66. Deutsch J, Rapoport SI, Rosenberger TA. Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered. Neurochem Res 2003;28(6):861-6.